Compound E, chemically designated as 209986-17-4, represents a significant exploration within the field of Alzheimer's disease research. This γ-secretase modulator was initially developed as a promising therapeutic treatment aimed at reducing the production of amyloid-beta peptides, which are believed to be central contributors to the formation of